Tomás Vila 2010a.

Methods	A patient report of visual hallucinations during methylphenidate treatment
Participants	Diagnosis of ADHD: DSM‐IV (subtype: combined) Age: 10 years old IQ: above 70 Sex: male MPH‐naïve: no Ethnicity: not stated Country: Spain Comorbidity: none stated Comedication: not stated Sociodemographics: lives with his grandmother
Interventions	Methylphenidate type: 50% immediate release and 50% extended release Methylphenidate dose: 30 mg/day (1 mg/kg/day) Administration schedule: not stated Duration of treatment: 2 weeks Treatment compliance: not stated
Outcomes	Serious adverse events: After 2 weeks of 50% immediate release and 50% extended release methylphenidate: visual hallucinations (insects on hands, feet, abdomen and thorax) with associated itching, initiated 2 hours after ingestion and ceased 5 hours after Discontinuation of methylphenidate and initiation of risperidone: no visual hallucinations No readministration of methylphenidate due to ethical reasons
Notes	Key conclusions of the study authors: this is the first patient report of visual hallucinations caused by 50% immediate release, 50% extended release methylphenidate, which is no wonder when you consider that the preparation has been marketed recently Funding/vested interests/authors' affiliations: not stated Supplemental information regarding diagnostic criteria and IQ received through personal email correspondence with the authors in September 2013 (Tomás 2013 [pers comm])